DKSH's Cambodian Services Deal with Bayer Gets 5 Year Extension

By Dan Stanton

- Last updated on GMT

Related tags: Marketing

DKSH and Bayer extend partnership in Cambodia
DKSH and Bayer extend partnership in Cambodia
DKSH says its contract extension with Bayer in Cambodia strengthens its position as a service provider for pharmaceutical companies throughout Southeast Asia.

The companies have worked together in the region for over ten years and this five year extension will see the Swiss market expansion service firm provide importation, custom clearance, logistics and distribution for Bayer Healthcare in Cambodia.

Michael Hofer, Communications Manager at DKSH told Outsourcing-Pharma.com that “Bayer is a regional partner of DKSH Healthcare”​ with the firm also providing services – including the distribution of Bayer’s prescription and OTC drugs – in Thailand and China.

Nicolas Chabanier, General Manager at DKSH Cambodia’ Healthcare Unit added in an official statement that the deal: “Strengthens our position as preferred Market Expansion Services partner for small and medium sized as well as big multinational pharmaceuticals companies who want to grow their business in Cambodia.”

The news comes months after DKSH secured further business in Southeast Asia with a services agreement extension for German biomanufacturing company Wacker Biotech​.

That deal saw DKSH take on responsibility for selling Wacker’s cyclodextrins, cysteine and cystine throughout the region.

Speaking in November, Wacker’s head of distribution management Jurgen Frisch said: “The markets in Southeast Asia are experiencing dynamic growth and becoming more and more important.”

Hofer said that according to statistics, collaborated from a number of sources (including DKSH’s internal data, market research company BMI,  and Cambodia’s Ministry of Health), the pharmaceutical market in Cambodia is worth an estimated $130m, business to business. Furthermore, according to Hofer, the market grew in 2012 at a rate of 10.6% with a growth of 8.8% forecasted for 2013.

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars